Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

IOR Income Opportunity Realty Investors, Inc.
$18.50 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy IOR stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 75.2M
Enterprise value 75.2M
Trailing PE 20.329561
PEG Ratio -0.69701352
Enterprise to EBITDA 14.887128885369
Enterprise to revenue 13.837852042694
Price to book MRQ 0.58937526
Price to sales TTM 13.843263341921

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 5.4M
EBITDA 4.7M
Diluted EPS TTM 0.91
Total Cash (MRQ) 29000
Current ratio (MRQ) 29169
Operating Cash Flow (TTM) -268000

IOR trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent IOR News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.